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Background: Fibroadenoma is the most common breast tumor in young women, and its growth and metabo-
lism may be under hormonal control. In the present paper we described the proteoglycan (PG) composition
and synthesis rate of normal breast and ﬁbroadenoma during the menstrual cycle.
Methods: Samples of ﬁbroadenoma and adjacent normal breast tissue were obtained at surgery. PGs were
characterized by agarose gel electrophoresis and enzymatic degradation with glycosaminoglycan (GAG) ly-
ases, and immunolocalized by confocal microscopy. To assess the synthesis rate, PGs were metabolic labeled
by 35S-sulfate.
Results: The concentration of PGs in normal breast was higher during the secretory phase. Fibroadenoma con-
tained and synthesized more PGs than their paired controls, but the PG concentrations varied less with the
menstrual cycle and, in contrast to normal tissue, peaked in the proliferative phase. The main mammary
GAGs are heparan sulfate (HS, 71%–74%) and dermatan sulfate (DS, 26%–29%). The concentrations of both in-
creased in ﬁbroadenoma, but DS increased more, becoming 35%–37% of total. The DS chains contained more
β‐D-glucuronic acid (IdoUA/GlcUA ratios were >10 in normal breast and 2–7 in ﬁbroadenoma). The 35S-sulfate
incorporation rate revealed that the in vitro synthesis rate of DSwas higher than HS. Decorin was present in both
tissues, while versican was found only in ﬁbroadenoma.
Conclusions: In normal breast, the PG concentration varied with the menstrual cycle. It was increased in
ﬁbroadenoma, especially DS.
General signiﬁcance
PGs are increased in ﬁbroadenoma, but their concentrations may be less sensitive to hormonal control.© 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Fibroadenoma, a benign tumor composed by stromal and glandu-
lar tissues, is the most common benign tumor among young women
in reproductive phase. Although 25% of affected women are asymp-
tomatic, multiple lesions may occur in 13–20% of them [1,2].
It is well known that the steroid hormones estrogen and progester-
one regulate the development of mammary gland and play a role in the
initiation and progression of breast cancer [3,4]. The estrogen receptor
(ER) and the progesterone receptor (PR) belong to the steroid hormonelycan; CS, chondroitin sulfate;
erum albumin; PBS, phosphate
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vier OA license. receptor family of ligand inducible transcription factors [5]. These hor-
mones play important roles in the control of proliferation and differen-
tiation of breast cells, but other tissue components and growth factors
may also be involved, underlining the complexity of these control
mechanisms [6–8].
In all animal tissues, the cells are located in a microenvironment
composed of a dynamic and complex array of collagens, glycopro-
teins, proteoglycans (PGs) and glycosaminoglycans (GAGs)—the ex-
tracellular matrix. Although most animal cells can only grow in vitro
when they are attached to surfaces through extracellular matrix,
which is also the substrate for cell migration, the extracellular matrix
provides muchmore than just mechanical and structural support. The
extracellular matrix has implications in developmental patterning,
stem cell niches and cancer. It also imparts spatial context for signal-
ing events through cell surface growth factor receptors and adhesion
molecules. Extracellular matrix macromolecules can determine the
cell behavior, proliferation, differentiation, migration, polarity, and
survival by communicating with the intracellular cytoskeleton and
playing a part in growth factor signaling.
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surface, and individual PGs interact speciﬁcally with other matrix
components, such as collagen, laminin and ﬁbronectin, as well as
with growth factors and cytokines [9–12]. These interactions may af-
fect cell growth, migration, adhesiveness, and differentiation. Some of
these functions are dependent on the protein core, while other rely
on the GAG side chains [13–15]. In breast tumors, as well as in a
wide variety of tumors, a signiﬁcant increase in the expression of
PGs and GAGs has been described, and the amount of extracellular
chondroitin sulfate (CS) in many tumors is high in comparison to
the normal tissue of origin [16,17]. However, themagnitude of this in-
crease and the PG structure vary widely depending on the size and
type of tumor [18–20].
On the other hand, the synthesis and degradation of GAGs and PGs
may be regulated by factors that control the development and func-
tion of mammary glands [21,22]. Although hormonal inﬂuence has
been reported upon breast tissue and malignant tumors [3,23], their
effects upon breast tissue GAGs and PGs have not been investigated.
Regarding benign tumors such as ﬁbroadenoma, the number of
studies is very low. The changes that occur in the extracellular matrix
as a consequence of hormonal ﬂuctuations during the menstrual cycle
are poorly understood. Concerning GAGs and PGs, there are even less
studies.
The aim of the present paper was to investigate the changes that
occur in ﬁbroadenoma GAGs and PGs in comparison to the normal
breast tissue during the menstrual cycle.
2. Material and methods
2.1. Patient selection
Patients attending the Department of Gynecology, Division of
Mastology, Section of Benign Mammary Diseases of Escola Paulista
de Medicina, UNIFESP, were initially selected if they had benign le-
sions. Only patients with ages ranging from 15 to 35 years and with-
out family history of breast cancer were included. Patients were
excluded from the study if they were using oral contraceptives, had
endocrine diseases, were pregnant or lactating during the lastTable 1
Characterization of menstrual cycle and tissue wet weight.
Patient # Age (years) Day of cycle Progesterone (ng/ml) Phase of the
9 18 2 1.7 Proliferative
27 27 2 1.8 Proliferative
16 21 4 1.0 Proliferative
22 20 4 0.9 Proliferative
23 27 4 0.3 Proliferative
15 22 6 1.1 Proliferative
11 17 8 0.2 Proliferative
19 35 8 0.7 Proliferative
10 22 9 0.9 Proliferative
4 22 11 0.7 Proliferative
6 28 12 0.7 Proliferative
18 16 12 0.5 Proliferative
5 19 13 0.5 Proliferative
13 16 14 2.2 Proliferative
25 24 14 0.6 Proliferative
7 18 16 28.3 Secretory
14 29 16 8.6 Secretory
20 27 17 10.1 Secretory
2 19 18 4.5 Secretory
21 17 19 4.1 Secretory
1 20 20 5.9 Secretory
8 30 23 4.9 Secretory
3 33 24 6.6 Secretory
12 19 25 7.2 Secretory
28 22 25 30.0 Secretory
26 24 27 12.8 Secretory
24 33 28 4.9 Secretory
17 30 30 3.3 Secretory12 months, or if the benign lesion turned out to be a manifestation
of a more serious breast condition.
Altogether 28 patients were included (Table 1). To better char-
acterize the phase of menstrual cycle, clinical and laboratory pa-
rameters were used. Blood was collected 30 min before surgery to
determine the serum progesterone levels by chemiluminescent en-
zyme immunoassay (DPC, Los Angeles, CA, USA), with an assay sen-
sitivity of 0.2 ng/ml [24]. The phase was considered secretory (or
luteal) when values were superior to 3 ng/ml. The study protocol
was previously approved by the Ethics Committee (Comitê de
Ética em Pesquisa—CEP) of Escola Paulista de Medicina, UNIFESP
(CEP 1090/09).
2.2. Tissue samples
Samples of ﬁbroadenoma and adjacent normal breast tissue, which
were used as matched controls, were obtained at surgery performed
at Hospital São Paulo, Sector of Breast Benign Disease, Depto. de
Ginecologia (Gynecology), Escola Paulista de Medicina—UNIFESP.
Shortly after surgical excision, the ﬁbroadenoma and normal breast tis-
sues were transferred to Depto. de Bioquímica (Biochemistry), Escola
Paulista de Medicina—UNIFESP, where all analyses were performed.
The tissue samples were dissected, weighed, carefully cut in small
pieces, and stored at−80 °C until use for PG extraction or immunoﬂu-
orescence. For metabolic labeling of PGs, small tissue samples
(200–500 mg.wetweight)were collected shortly after surgical excision
and, under sterile conditions, were transferred to tissue culture ﬂasks as
described in Section 2.4.
2.3. PG extraction
Each sample (350–550 mg, wet weight) was grinded in liquid ni-
trogen, and incubated with 10 volumes (3.5–5.5 ml) of 4 M guani-
dine hydrochloride (GuHCl, Aldrich Chemical Co. Inc, Milwaukee,
WI, USA) in 0.05 M sodium acetate buffer, pH 6.5, containing prote-
ase inhibitors (0.1 M -aminocaproic acid, 6.5 mM benzamidine,
5.5 mM iodocetamide and 0.1 M phenylmethylsulfonyl ﬂuoride), as
previously described [17,25]. After overnight incubation at 4 °Cmenstrual cycle Fibroadenoma wet weight (mg) Normal wet weight (mg)
398.1 490.5
1471.5 3286.7
216.8 265.0
190.7 241.5
251.1 375.4
195.4 465.6
296.0 376.0
339.1 332.3
525.8 655.0
394.0 681.0
103.2 213.1
595.6 122.0
1470.0 532.0
547.0 533.6
360.0 533.7
385.0 639.4
340.2 330.4
146.1 189.6
431.5 282.1
223.6 302.9
298.5 190.2
396.1 435.3
141.3 499.7
288.0 229.0
1052.0 725.0
505.5 1150.0
342.0 552.0
237.7 338.9
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were precipitated by slow addition of methanol (3 volumes) to the
supernatant. Subsequently, the precipitates formed after 18 h at
−20 °C were collected by centrifugation (1300×g, 15 min), washed
with 80% methanol, and vacuum‐dried. The dried material was
resuspended in water (350–550 μl, 1 μl/mg of initial wet weight),
and the solutions were stored at −20 °C.
To assess the efﬁciency of the extraction procedure, the debris (re-
sidual tissue not solubilized by GuHCl) were submitted to proteolysis
(2 mg/ml papain in 0.05 M phosphate-cysteine buffer pH 6.5, con-
taining 20 mM EDTA, 1 ml per 100 mg of initial wet tissue), as previ-
ously described [26]. After overnight incubation at 50 °C, nucleic acids
and proteins were removed by precipitation with 10% TCA in 1 M
NaCl (10 min, ice bath), and the GAGs were precipitated from the su-
pernatant by the slow addition of 3 volumes of methanol, under agi-
tation. After overnight at −20 °C, the precipitate formed was
collected by centrifugation, vacuum-dried, resuspended in 100 μl of
water, and stored at−20 °C. The PG and the GAG samples were ana-
lyzed by a combination of agarose gel electrophoresis and enzymatic
degradation with speciﬁc GAG lyases, as described in Section 2.5.
2.4. Metabolic labeling with 35S-sulfate
For metabolic labeling of PGs, small tissue samples (200–300 mg,
wet weight) were collected immediately after surgery and, under
sterile conditions, washed with 5 ml of phosphate buffered saline
(PBS) containing gentamicin (4 mg/ml), and transferred to tissue cul-
ture ﬂasks containing 10 ml of F12 medium, antibiotics (penicillin,
10,000 U; streptomycin 100 mg), and 35S-sulfate (50 μCi/ml, IPEN-
CNEN, São Paulo, SP, Brazil). The tissue explants were maintained at
37 °C in a 2.5% CO2 atmosphere, and after 24 h, the medium and the
tissue explants were collected and processed separately. The PGs
were precipitated from the conditioned culture medium by careful
and slow addition of methanol (2 volumes), and after 18 h at
−20 °C, the precipitate formed was collected by centrifugation,
dried and resuspended in 1 ml of water for analysis. The PGs were
extracted from the tissue explants as described in Section 2.3.
2.5. Characterization of PGs and GAGs
GAGs were released from the core proteins by proteolysis with pa-
pain (2 mg/ml in 0.06 M phosphate-cysteine buffer pH 6.5 and
20 mM EDTA) as previously described [17]. Aliquots of the intact
PGs or GAGs (5 μl containing 0.5–5 μg) were submitted to agarose
gel electrophoresis in 0.05 M 1,3-diaminopropane-acetate buffer, pH
9 (PDA) [27]. After ﬁxation with cetyltrimethylammonium bromide
and Toluidine Blue staining, PGs and GAGs were quantiﬁed by
densitometry of the gel slabs (Scanner CS-9000, Shimadzu). These
compounds were further characterized by enzymatic degradation
with bacterial GAG lyases (chondroitin AC lyase, chondroitin B lyase
and heparitinase II from Flavobacterium heparinum), prepared [28,29]
and incubated [30] as previously described. Chondroitin AC lyase (EC
4.2.2.5) acts only on β‐D-glucuronic acid-containing regions of CS and
dermatan sulfate (DS),while chondroitin B lyase (EC 4.2.2.19) is speciﬁc
for α‐L-iduronic acid-containing regions of DS [31]. Heparan sulfate
(HS) is resistant to both chondroitinases, but is depolymerized by
heparitinase II. Brieﬂy, aliquots of either PGs or GAG free chains
(50–100 μg) were incubated with 2×10−4units of enzymes in 0.05 M
ethylenediamine-acetate buffer pH 8.0 (for chondroitin lyases) or 7.0
(for heparitinase II), in a ﬁnal volume of 20 μl). After 6 h incubations
at the optimum temperature of each enzyme (37 °C for chondroitin
AC lyase, 20 °C for chondroitin B lyase and 30 °C for heparitinase II),
aliquots of the incubationmixtures were submitted to agarose gel elec-
trophoresis (5 μl) and paper chromatography (15 μl, Whatman No. 1
paper, isobutyric acid/1.25 M NH3, 5:3, v/v, 24 h). The degradation
products were visualized in the paper chromatograms by alkaline silvernitrate staining. The iduronic acid (IdoUA) and glucuronic acid (GlcUA)
contents of the galactosaminoglycans (CS and DS) were estimated from
the amounts of IdoUA-GalNAc(SO4) and GlcUA-GalNAc(SO4) disaccha-
ride repeating units formed by chondroitinases B and AC, respectively.
Polyacrylamide gel electrophoresis of the PGs and GAGs was per-
formed in a Bio-Rad Mini-Protean System. Samples were mixed
with sample buffer containing 3% SDS and heated for 10 min at
100 °C. Aliquots (5–10 μl) were applied to gradient gels (3–20%)
and run for 4–5 h at 5 V/cm. Gels were stained with 0.2% silver nitrate
as previously described [32].
Further identiﬁcation of decorin and versican was performed by
immunoblotting, as described by Sambrook et al. [33]. After either
agarose or polyacrylamide gel electrophoresis, intact PGs and their
core proteins were transferred to nitrocellulose membranes. After
blocking, membranes were probed with either rabbit polyclonal
anti-human decorin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA, Decorin H-80, sc-22753) or mouse monoclonal anti-versican
(Seikagaku Kogyo Company Ltd., Tokyo, Japan, clone 2-B-1, catalog
number 270428) (1:3000) in 1% bovine serum albumin (BSA) in
PBS. Then, the membranes were washed with PBS and incubated
with the appropriate peroxidase-conjugated secondary antibody
(Millipore, Temecula, CA, USA, catalog numbers AP304P and 12‐
349). The antibody binding was visualized through either enhanced
chemiluminescence substrate (Pierce ECL Thermo Scientiﬁc, Rockford,
IL, catalog number 32209) or 3-3′ diaminobenzidine (DAB, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA, sc‐209686).
The 35S-sulfate labeled compounds were visualized by exposure of
the gel slabs or paper chromatograms to a Packard Cyclone TM Storage
Phosphor System by 24 h. For quantiﬁcation, the bands containing
radiolabeled compounds were counted in a liquid scintillation spec-
trophotometer, using Ultima Gold LSC-Cocktail (Packard Instruments
Company Inc., Downers Grove, IL, USA). The quantitative results
were always corrected for 35S-decay.
2.6. Histology and confocal microscopy
The confocal microscopy was performed as already described [17],
with a few modiﬁcations. In brief, tissues were ﬁxed in 4% parafor-
maldehyde in PBS. After 18 h, they were washed in PBS and
maintained in 30% sucrose in PBS, at room temperature. After 24 h,
the tissues were frozen in Tissue Freezing Medium (Leica Instruments
G., Nussloch, Germany) and stored at−20 °C. They were cut in 20 μm
sections in cryostat, washed 10 times in PBS, incubated with 0.1 M
glycine in PBS for 1 min, washed 5 times with PBS, incubated with
1% BSA in PBS for 10 min, and washed with PBS 10 times. For double
immunoﬂuorescence labeling studies, cryosections were incubated
for 1 h with two primary antibodies: ﬁrst anti-decorin and then
anti-versican (both diluted 1:50 in 1% BSA-PBS). The cryosections
were washed 10 times in PBS (30 s each), and subsequently Alexa-
Fluor-conjugated appropriate secondary antibodies (1:50 dilution in
PBS) were applied for 1 h. Alexa-Fluor 488 goat anti-rabbit IgG conju-
gate (green) and Alexa-Fluor 594 goat anti-mouse IgG conjugate (red,
Molecular Probes, Eugene, OR, USA) were used. Alternatively, pro-
teins of the cytoskeleton (actin ﬁlaments) were labeled by incubation
with Alexa-Fluor 586-Phalloidin (1:150 dilution in PBS, 1 h). DNA
was labeled by incubation with DAPI (4′,6-diamidino-2-phenylindole,
dihydrochloride, Molecular Probes, Eugene, OR, USA, 1:1000 dilution
in PBS, 5 min). The cryosections were washed 10 times in PBS and a
ﬁnal rinse in distilled water, coverslips were mounted with Fluo-
romount G/PBS (2:1) (ElectronMicroscopy Sciences, Fort, Washington,
PA, USA), and observed in a Nikon Eclipse E600 microscope equipped
with CF160 epi-ﬂuorescence optics. Confocal images were obtained
with a Carl Zeiss LSM510 Confocal Microscope.
For histology images, the tissues were cut in 12 μm sections in
cryostat, transferred to gelatin-coated slides, dehydrated, rehydrated,
and stained by hematoxylin and eosin (H&E). Images were obtained
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Image Pro-Plus 5.1 software.
2.7. Statistical analyses
Bartlett's test was used to test if groups are homoscedastic. One-
way ANOVA with Dunnett’ spot test and Student's t-test were per-
formed using JMP Statistical Discovery 8. Signiﬁcance was deﬁned
by P values less than 0.05.
3. Results
3.1. PGs and GAGs from ﬁbroadenoma and adjacent normal breast tissue
Fig. 1A shows a representative agarose gel electrophoresis of PGs
extracted from ﬁbroadenomas (F) and their respective adjacent nor-
mal tissues (N). PGs from both normal and tumoral tissues migrated
as a single broad band, and were quantiﬁed by densitometry of the
agarose gel slabs. Means±standard errors of three measurements
for each sample (56 samples, 28 ﬁbroadenomas and their respective
matched controls) are shown in Fig. 1B. The yield of the extraction
procedure was always high (>90%), as assessed by the quantiﬁcationFig. 1. PGs from human normal breast and ﬁbroadenoma in the proliferative and secretory
adjacent breast tissue (N) as described in Section 2.3. Aliquots (5 μl) were submitted to ag
Section 2.5. (A) Representative agarose gel electrophoresis of PGs extracted from patients
slabs, and (B) shows quantitative results (mean±standard error, brackets indicate differen
mean of three measurements for each sample. S, mixture of standard GAGs; CS, chondroitiof the residual GAGs after total solubilization of tissues by proteolysis.
In normal breast, the mean PG concentration was higher in the secre-
tory phase of the menstrual cycle (Pb0.01), and in ﬁbroadenoma the
PG concentration was always increased in comparison to normal.
Nevertheless, in contrast to normal tissues, the mean PG concentra-
tion in ﬁbroadenoma did not signiﬁcantly vary with the phases of
the menstrual cycle. The magnitude of PG increase in ﬁbroadenoma
varied from 1.5 to 6 times in different cases, and the differences be-
tween ﬁbroadenoma and normal breast were statistically signiﬁcant
in both phases of the menstrual cycle. Fig. 1C that shows that, in nor-
mal breast, the PG concentration ﬂuctuates with the menstrual cycle,
exhibiting a broad and high peak during the secretory phase. In con-
trast, although a ﬂuctuation also occurred in ﬁbroadenoma, the
highest peak occurred during the proliferative phase.
To further characterize the PGs, the GAG chains were released by
proteolysis and submitted to agarose gel electrophoresis in PDA buff-
er. Two main bands appeared in both tissues (Fig. 2A), migrating as
DS and HS, although the DS from ﬁbroadenoma migrated as a more
polydisperse band. The identiﬁcation of these GAGs was conﬁrmed
by incubation with speciﬁc GAG lyases, and the iduronic acid- and
glucuronic acid-contents of DS were estimated by the action of chon-
droitin B and AC lyases, respectively. Fig. 2B shows that, during thephases of the menstrual cycle. PGs were extracted from ﬁbroadenoma (F) and normal
arose gel electrophoresis in PDA buffer and stained by Toluidine Blue, as described in
27, 1, 3 and 9 (see Table 1). PGs were quantiﬁed by densitometry of the agarose gel
ces that were statistically signiﬁcant). (C) Shows individual data. Each point represents
n sulfate; DS, dermatan sulfate; HS, heparan sulfate, Or., origin.
Fig. 2. GAGs from human normal breast (N) and ﬁbroadenoma (F) in proliferative and
secretory phases of the menstrual cycle. (A) GAGs released by proteolysis from PGs
were analyzed by agarose gel electrophoresis in PDA buffer, which separates chondroi-
tin sulfate (CS) dermatan sulfate (DS) and heparan sulfate (HS). The identiﬁcation
of these compounds was conﬁrmed by incubation with speciﬁc GAG lyases, and the
β-D-glucuronic acid (GlcUA) and α-L-iduronic acid (IdoUA) contents of DS were esti-
mated by degradation with chondroitin AC and B lyases. The average concentration
of GAGs±standard error is shown in (B). Brackets indicate differences that were statis-
tically signiﬁcant.
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the glucuronic acid-contents of DS was very low (IdoUA/GlcUA ratios
>10). In ﬁbroadenoma, the contents of glucuronic acid were in-
creased, and the iduronic acid contents decreased in the secretory
phase (IdoUA/GlcUA ratios 7.58 and 2.19 in proliferative and secreto-
ry phases, respectively). In both phases, the ﬁbroadenoma DS was
increased in comparison to normal breast, going from 26%–29% of
total GAGs to 35%–37%, especially concerning its glucuronic acid-
containing regions.
3.2. Metabolic labeling of PGs
To investigate the PG synthesis rate, 50 tissue samples (25
ﬁbroadenoma and 25 normal adjacent breast tissue, used as paired
controls), obtained immediately after surgery, were transferred to tis-
sue culture ﬂasks containing F12 medium and 35S-sulfate. After 24 h
at 37 °C, both the conditioned medium and the tissue explants were
collected and analyzed for 35S-PGs, as described in Section 2.4.
Fig. 3 shows a representative agarose gel electrophoresis of PGs
extracted from ﬁbroadenoma and normal breast, analyzed by Toluidine
Blue staining (Fig. 3A) and radioautography (Fig. 3B). Upon Toluidine
Blue staining, only the standard GAGs were visualized due to the low
amounts of PGs, while radioautography showed two main bands, both
in conditioned culture medium (M) and tissue explants (PG). Small
amounts of 35S-GAGs were isolated from the tissue residues (after
PG extraction by GuHCl), migrating as sharp bands (GAG). Fig. 3Cshows that the 35S incorporation rate in PGs was higher in almost all
ﬁbroadenoma samples (except for one case in each phase), in compar-
ison to their respective matched controls. The magnitude of this in-
crease varied among different samples, but the differences between
normal and tumoral tissues were signiﬁcant for both tissue and medi-
um 35S-PGs (Fig. 3D).
To further characterize these compounds, the GAG chains were
released from the 35S-PGs by proteolysis, and characterized. Fig. 4A
shows that the main GAGs from both normal breast and ﬁbro-
adenoma migrated as 35S-DS and 35S-HS. Nevertheless, the incorpo-
ration of 35S-sulfate in DS was higher than in HS, possibly due to a
higher turnover rate of this GAG. The identiﬁcation of these com-
pounds was conﬁrmed by degradation with chondroitin AC lyase,
chondroitin B lyase and heparitinase II. Both 35S-DS and 35S-HS
were increased in ﬁbroadenoma, in comparison to normal breast
(Fig. 4B).
Fig. 5 shows that the ﬁbroadenoma 35S-DS contained increased
amounts of GlcUA in comparison to normal breast, both 4-sulfated
and 6-sulfated disaccharide units (Di4S-GlcUA and Di6S-GlcUA, re-
spectively). The ﬁbroadenoma/normal breast ratios were lower for
4-sulfated iduronic acid-containing disaccharides (Di4S-IdoUA), and
no 6-sulfated iduronic acid-containing disaccharides (Di6S-IdoUA)
were found.
3.3. Immunoblotting of extracellular matrix PGs
The core protein of extracellular matrix PGs was identiﬁed by im-
munoblotting. Decorin was detected in both normal breast tissue and
ﬁbroadenoma, during all the menstrual cycle, at higher concentra-
tions in ﬁbroadenoma (Fig. 6). In contrast, versican was detected
only in ﬁbroadenoma, at higher concentrations during the secretory
phase of the menstrual cycle. The decorin core protein was also
detected after incubation of the PGs with chondroitin AC and B lyases
(Fig. 6).
3.4. Histology and confocal microscopy
Fig. 7 shows representative images of normal breast and ﬁbro-
adenoma obtained during the proliferative and the secretory phases
of the menstrual cycle.
The distribution of decorin and versican in normal breast and
ﬁbroadenoma was analyzed by confocal microscopy, and Fig. 8
shows that decorin (green) occurs in both normal tissue and
ﬁbroadenoma, especially in the intra-lobular stroma, in both phases
of the menstrual cycle, while versican (red) was detected only in
ﬁbroadenoma.
4. Discussion and conclusions
4.1. Discussion
Fibroadenomas are benign tumors of the breast typically com-
posed of stromal and epithelial cells. Since they arise from lobules,
it is not surprising that they occur predominantly in women in the
15–25 age group, when the main feature of breast development is
the addition of lobular structures to the already developing duct
system.
Fibroadenomas comprise about 50% of all breast biopsies, and
this rate rises to 75% for biopsies in women under the age of
20 years [2,34]. The tumors are round or ovoid, elastic, nodular,
and have a smooth surface. Approximately 90% of ﬁbroadenomas
are less than 3 cm in diameter, indicating that its growth is usually
self-limited, but despite their prevalence, the mechanisms control-
ling ﬁbroadenoma development and growth are poorly understood.
Analyses of the cellular components of ﬁbroadenomas demon-
strated that both the stromal and the epithelial cells are polyclonal
Fig. 3. Agarose gel electrophoresis of 35S-PGs from normal breast (N) and ﬁbroadenoma (F) tissue explants. Fibroadenoma and adjacent normal breast samples (200–500 mg, wet
weight) were metabolically labeled with 35S-sulfate. 35S-PGs were isolated from the conditioned media (M) and the tissue explants (PG), and then tissue residues were submitted
to total proteolysis and the 35S-GAGs were also analyzed (GAG). These compounds were analyzed by agarose gel electrophoresis (PDA buffer), and localized in the gel by Toluidine
Blue staining (A) and radioautography (B). The radioactivity of the bands containing 35S-labeled compounds was quantiﬁed as described in Section 2.4. Individual paired results,
and mean±standard error are shown in (C) and (D), respectively. Brackets indicate statistically signiﬁcant differences between normal and tumoral tissue explants. S, standard
mixture of GAGs; CS, chondroitin sulfate; DS, dermatan sulfate; HS, heparan sulfate.
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perplastic processes associated with aberration of the normal
maturation of the breast, rather than true neoplasms [36]. The prolif-
eration forms duct-like spaces surrounded by ﬁbroblastic stroma.
The growth of normal breast epithelial cells is controlled by the
ovarian steroid hormones estrogen and progesterone, as well as by
cytokines and associated transcription factors, suggesting that multi-
ple receptor signaling pathways could be involved in its growth and
differentiation [37,38]. The synthesis of extracellular matrix macro-
molecules is also controlled by cytokines and hormones, and a recip-
rocal regulation of extracellular matrix proteins and ovarian steroid
activity has been demonstrated in the mammary gland [39]. In fact,
an antimetastatic role has been proposed for decorin, a member ofthe small leucine-rich proteoglycan gene family and the main PG of
breast extracellular matrix [40]. It is possible that the production of
extracellular matrix components in ﬁbroadenomas is also under hor-
monal control. The epithelium is of normal appearance, but it was
shown that the characteristic cyclic behavior that occurs in normal
mammary epithelium with the menstrual cycle does not occur in
ﬁbroadenoma epithelium: there was no difference in the mitotic
index and nuclear volume between proliferative and secretory phases
[41], suggesting that endocrine hormones are not the main control
mechanism in ﬁbroadenoma growth. Our results on GAG and PG syn-
thesis seem to corroborate this notion.
The present paper describes the ﬁbroadenoma and the normal
breast PGs, as well as the PGs synthesized under tissue culture
Fig. 4. 35S-GAG chains released from PGs. The 35S-GAG chains were released from 35S-PGs by proteolysis, and identiﬁed by a combination of agarose gel electrophoresis and enzy-
matic degradation with speciﬁc GAG lyases. 35S-GAGs from ﬁbroadenoma (F) and from normal breast (N), both intact and after incubation with chondroitin AC lyase (AC), chon-
droitin B lyase (B), and heparitinase II (H), were analyzed by agarose gel electrophoresis and localized in the gel slabs by Toluidine Blue staining and radioautography (A). (B) Shows
the quantitative data (mean±standard error) for 35S-HS and 35S-DS released from tissue explants (Tissue) and conditioned culture medium (Medium).
Fig. 5. Ratio ﬁbroadenoma/normal breast of 35S-labeled DS disaccharides in prolifera-
tive and secretory phases of the menstrual cycle. The amounts of 4-sulfated and 6-
sulfated disaccharide units containing either β-D-glucuronic acid (Di4S-GlcUA and
Di6S-GlcUA) or α-L-iduronic acid (Di4S-IdoUA and Di6S-IdoUA) in DS chains were
measured after incubation with chondroitin AC or B lyases and analysis of their degra-
dation products.
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The “normal breast” here studied is adjacent to diseased tissue, and
all investigated tissues were derived from ﬁbroadenoma patients.
Only six of the 28 patients here studied were parous (22 nulliparous).
In normal breast, the PG concentration ﬂuctuated with the men-
strual cycle, achieving higher concentrations during the secretory
phase (it is important to notice that, in the present paper, PGs were
quantiﬁed by their GAG contents).
In ﬁbroadenoma, the PG concentration also oscillated, but there
was no difference between the mean values obtained during the pro-
liferative and the secretory phases. Nevertheless, the PG concentra-
tion was always higher in ﬁbroadenoma than in normal breast.
The main breast GAGs were HS (71%–74%) and DS (26%–29%).
Both GAGs increased in ﬁbroadenoma, but DS increased more, be-
coming 35%–37% of total.
Chondroitin sulfate (CS)/DS proteoglycans are ubiquitous com-
pounds of extracellular matrices that have been implicated in several
biological processes, such as cell signalling, proliferation and would
healing (review in [42]). CS and DS chains consist of repeating disaccha-
ride units of uronic acid (UA) and N-acetylgalactosamine (GalNAc). The
only UA found in CS is β‐D-glucuronic acid (GlcUA), while DS contains
also its C5-epimer α‐L-iduronic acid (IdoUA). The epimerization of
GlcUA to IdoUA in DS is catalyzed by two DS-epimerases, recently
cloned and named DS-epi1 and DS-epi2 [43]. The presence of IdoUA in-
creases the chain conformational ﬂexibility, which facilitates interac-
tions, and is critical in mediating several DS biological functions, such
as binding to growth factors [44] and heparin cofactor II [45].
IdoUAmoieties in DS can be clustered together to form long blocks
or interspersed among unmodiﬁed GlcUA moieties. It was recently
shown that reduced expression of either DS-epimerase affects IdoUA
block formation, and it is possible that the relative abundance of the
two enzymes might be a regulatory mechanism for the IdoUA amounts
and distribution [43]. The expression of DS-epimerase (SART2, [46])
Fig. 6. SDS-PAGE (silver staining) and immunoblotting of PGs from normal breast tissue and ﬁbroadenoma probed with either anti-decorin or anti-versican antibodies. PGs
extracted from normal breast tissue (N) and ﬁbroadenoma (F), obtained either during the proliferative or the secretory phase of the menstrual cycle, were incubated with chon-
droitin B lyase (B) or chondroitin AC lyase (AC). Intact PGs (I) were incubated with heat inactivated enzymes. Intact and chondroitin lyase-treated PGs were submitted to SDS-PAGE
(3–20% gradient). The bands were visualized by silver staining (SDS-PAGE) and by Western blotting probed with anti-decorin antibody. The Mr of prestained protein standards is
shown for SDS-PAGE gel. Intact PGs were also analyzed by agarose gel electrophoresis in PDA buffer, transferred to nitrocellulose membranes, and probed with either a polyclonal
anti-decorin antibody (Decorin) or a monoclonal anti-versican antibody (Versican). Abbreviations used are: F-S, PGs from ﬁbroadenoma, secretory phase; F-P, PGs from
ﬁbroadenoma, proliferative phase; N-P, PGs from normal breast, proliferative phase; N-S, PGs from normal breast, secretory phase; Or., origin.
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methods and in situ hybridization [47].
Furthermore, CS and DS chains can also be modiﬁed by sulfation
of positions 4 and 6 of GalNAc and position 2 of UA by speciﬁcFig. 7. Optical microscopy of ﬁbroadenoma and adjacent normal breast during the prolifer
surgery were ﬁxed with 4% buffered formaldehyde, cut in 12 μm sections in cryostat,
Bar=50 μm.sulfotransferases, and sulfation patterns also affects the biological func-
tions of these compounds [48]. The epimerization affects the sulfation.
For instance, the long IdoUA-GalNAc stretches are never found with 6-
sulfates on GalNAc. Our results are in agreement with these data.ative and the secretory phases of the menstrual cycle. Tissue samples collected during
transferred to gelatin-coated slides, dehydrated, rehydrated, and stained with H&E.
Fig. 8. Confocal microscopy for decorin (B, green) and versican (C, red) of human normal breast and ﬁbroadenoma. Normal breast and ﬁbroadenoma cryostat sections were double
immunostained with polyclonal rabbit anti-decorin (B, green) andmonoclonal mouse anti-versican antibodies (C, red). Nucleus was stained by DAPI (A, blue), and D shows overlaid
images. The images were obtained by confocal microscopy. Note that versican was detected only in ﬁbroadenoma. Bars=20 μm.
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polymer, containing three types of disaccharide units: (A) 2-
acetamido-2-deoxy-3-O-(β‐D-glucuronic acid)-4-O-sulfo‐D-galactose;
(B) 2-acetamido-2-deoxy-3-O-(α‐L-iduronic acid)-4-O-sulfo‐D-
galactose; (C) 2-acetamido-2-deoxy-3-O-(β‐D-glucuronic acid)-6-O-
sulfo‐D-galactose. Type (C) disaccharides (6-sulfated) were not
detected in normal breast DS, and the increased amounts of types (A)
and (C) in ﬁbroadenoma indicate that the GlcUA/IdoUA ratio was in-
creased in comparison to normal breast. It is possible that the polymers
synthesized in ﬁbroadenoma were not completely processed, maybe
due to limiting activities of DS-epimerases. This possibility was also
raised by others, who analyzed benign and malignant tumors of the
uterus [20,49].
Concerning the protein core, the main extracellular matrix PG
found in normal breast was decorin. Hallberg et al. [50] reported the
gene expression (mRNA) decorin (and also syndecan-1 and ‐4) in
normal breast, and found a decrease in decorin expression in the se-
cretory phase, only for parous women. The glycosylation was not an-
alyzed. In the present study, increased concentrations of decorin were
found in ﬁbroadenoma, which also contained versican, a highmolecular weight PG of the hyalectan gene family. Versican was not
found in normal breast. Decorin (and also versican in ﬁbroadenoma)
was concentrated in the periductal regions (lobular stroma) of nor-
mal and tumoral tissues.
Increased expression of versican has been detected in many ma-
lignant tumors, and is associated with the degree of tumor malignan-
cy [51,52]. Versican was also found to be overexpressed in uterine
leiomyoma [53], and its distribution and expression were found to
be regulated by steroid hormones in mouse uterus [54]. To our
knowledge, this is the ﬁrst study to document the expression of ver-
sican in ﬁbroadenoma.
The increased expression of decorin here reported could explain
the self-limited growth of ﬁbroadenoma. The decorin core protein
modulates collagen ﬁbrillogenesis and matrix assembly [55], and it
has been shown that it negatively regulates the growth of a variety
of tumor cells. It speciﬁcally binds and down-regulates the epidermal
growth factor (EGF) receptor and blocks the transforming growth fac-
tor β (TGF-β) signaling pathway [56,57]. Decorin causes reduction of
ErbB2 levels in tumor xenografts in vivo, and prevents metastatic
spreading to the lungs [39]. Low levels of decorin in invasive breast
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tients expressing high levels [58]. Furthermore, it was recently
shown that decorin has antiangiogenic activities [59], while the
tumor associated chondroitin sulfate seems to inhibit metastasis
[60]. Decorin was proposed as a therapeutic agent against breast can-
cer due to its inhibition of tumor growth and metastatic spreading
[39].
4.2. Conclusions
Taken together, these data highlight the relevance of PGs in the
regulation of tumor biology. Our results demonstrate that the synthe-
sis rate and the concentration of PGs is increased in ﬁbroadenoma as
compared to normal breast, but the menstrual cycle has less inﬂuence
on ﬁbroadenoma than on normal breast PGs. Decorin was the main
extracellular matrix PG expressed in both normal and tumoral tissues,
at higher concentrations in the lobular stroma, while versican was
found only in ﬁbroadenoma. These changes may be related to modiﬁ-
cations in the tissue architecture that lead to changes in the control of
cell proliferation, adhesion and migration.
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